About Sestrin-2
Sestrin-2 (SESN2) is a protein
from Homo sapiens identified by UniProt accession
P58004, 480 residues long.
MolForge cross-references it against 0 known binders and
239 disease associations.
Target properties
| Protein name | Sestrin-2 |
| UniProt accession | P58004 |
| Gene | SESN2 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (239)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.32
- eosinophil count · score 0.23
- breast adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.19
- endometrial cancer · score 0.18
- squamous cell lung carcinoma · score 0.18
- lung adenocarcinoma · score 0.18
- eosinophil percentage of leukocytes · score 0.16
- neoplasm · score 0.10
- hepatocellular carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P58004-F1 | alphafold | PREDICTED | 81.37 | — |
Amino-acid sequence (480 residues)
MIVADSECRA ELKDYLRFAP GGVGDSGPGE EQRESRARRG PRGPSAFIPV EEVLREGAES LEQHLGLEAL MSSGRVDNLA VVMGLHPDYF TSFWRLHYLL LHTDGPLASS WRHYIAIMAA ARHQCSYLVG SHMAEFLQTG GDPEWLLGLH RAPEKLRKLS EINKLLAHRP WLITKEHIQA LLKTGEHTWS LAELIQALVL LTHCHSLSSF VFGCGILPEG DADGSPAPQA PTPPSEQSSP PSRDPLNNSG GFESARDVEA LMERMQQLQE SLLRDEGTSQ EEMESRFELE KSESLLVTPS ADILEPSPHP DMLCFVEDPT FGYEDFTRRG AQAPPTFRAQ DYTWEDHGYS LIQRLYPEGG QLLDEKFQAA YSLTYNTIAM HSGVDTSVLR RAIWNYIHCV FGIRYDDYDY GEVNQLLERN LKVYIKTVAC YPEKTTRRMY NLFWRHFRHS EKVHVNLLLL EARMQAALLY ALRAITRYMT
Explore Sestrin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets